Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.
Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.